GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BSP:N1VS34) » Definitions » Cyclically Adjusted Book per Share

Novartis AG (BSP:N1VS34) Cyclically Adjusted Book per Share : R$15.21 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Novartis AG Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2024 was R$96.830. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$15.21 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -2.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -0.70% per year. And the median was 3.45% per year.

As of today (2024-05-26), Novartis AG's current stock price is R$52.25. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$15.21. Novartis AG's Cyclically Adjusted PB Ratio of today is 3.44.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.77.


Novartis AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 16.65 17.52 17.19 15.94

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.70 16.08 16.95 15.94 15.21

Competitive Comparison of Novartis AG's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=96.83/107.3549*107.3549
=96.830

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 64.874 101.517 68.605
201409 68.946 101.247 73.105
201412 77.943 100.704 83.091
201503 99.131 100.339 106.063
201506 101.478 100.464 108.439
201509 124.973 99.785 134.453
201512 125.954 99.386 136.053
201603 111.522 99.475 120.356
201606 104.168 100.088 111.731
201609 102.689 99.604 110.680
201612 105.720 99.380 114.204
201703 89.354 100.040 95.888
201706 98.344 100.285 105.277
201709 97.742 100.254 104.665
201712 105.453 100.213 112.968
201803 100.022 100.836 106.489
201806 124.761 101.435 132.042
201809 138.625 101.246 146.990
201812 132.093 100.906 140.535
201903 78.091 101.571 82.538
201906 86.520 102.044 91.023
201909 95.546 101.396 101.161
201912 100.526 101.063 106.784
202003 108.675 101.048 115.459
202006 121.975 100.743 129.980
202009 129.353 100.585 138.060
202012 129.022 100.241 138.179
202103 126.811 100.800 135.058
202106 121.494 101.352 128.690
202109 133.966 101.533 141.648
202112 171.182 101.776 180.566
202203 138.411 103.205 143.977
202206 145.514 104.783 149.086
202209 148.264 104.835 151.828
202212 146.854 104.666 150.626
202303 129.306 106.245 130.657
202306 121.672 106.576 122.562
202309 91.698 106.570 92.374
202312 111.867 106.461 112.806
202403 96.830 107.355 96.830

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Novartis AG  (BSP:N1VS34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=52.25/15.21
=3.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.77.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (BSP:N1VS34) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (BSP:N1VS34) Headlines

No Headlines